Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AstraZeneca PLC (GB:AZN)
LSE:AZN
AstraZeneca (AZN) Share Price & Analysis
364 Followers
AZN Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range9,314.90p - 12,704.00p
Previous Close12,106p
Volume84.82K
Average Volume (3M)2.00M
Market Cap
£187.68B
Enterprise Value205.33B
Total Cash (Recent Filing)$5.84B
Total Debt (Recent Filing)$28.62B
Price to Earnings (P/E)37.3
Beta0.88
Next Earnings
Jul 25, 2024EPS Estimate
£1.53Last Dividend Ex-Date
Feb 22, 2024Dividend Yield1.88%
Share Statistics
EPS (TTM)3.25
Shares Outstanding1,550,189,338
10 Day Avg. Volume2,944,327
30 Day Avg. Volume2,002,898
Standard Deviation0.06
R-Squared0.09
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)-12.86
Price to Sales (P/S)486.49
Price to Cash Flow (P/CF)22.20
P/FCF Ratio27.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.63
Enterprise Value/Gross Profit5.47
Enterprise Value/Ebitda22.60
Forecast
1Y Price Target
13,206.38pPrice Target Upside7.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
AstraZeneca News
PremiumCompany Announcements
AstraZeneca Acquires Amolyt Pharma for $1.05 Billion
Bulls Say, Bears Say
Bulls Say
Pipeline PotentialAZN has 5 game-changing Phase III reads for key assets with a total sales potential of around $20 billion.
Revenue And ReratingAZN's new mid-term guide implies 30E revenues 20% above consensus and 30E EBIT at the bottom end of margin guide 10% above consensus.
Sales GrowthSolid key sales drivers (Imfinzi +14%, Farxiga +25%, Fasenra +4%), with a notable acceleration in oral oncology franchises (Tagrisso +6%, Lynparza +5%, Calquence +14%).
Bears Say
Competitive LandscapeJNJ's SubQ Rybrevant represents a more convenient and tolerable offering than IV, likely increasing competition for MARIPOSA in NSCLC.
Financial GuidanceThe company updated currency assumptions, now expecting a mid single digit adverse impact on core EPS.
Regulatory ApprovalThere is no statistically significant overall survival benefit in the intent-to-treat overall population, raising questions about FDA acceptance.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.16% Insiders
14.72% Mutual Funds
8.59% Other Institutional Investors
76.53% Public Companies and
Individual Investors
AZN FAQ
What was AstraZeneca PLC’s price range in the past 12 months?
AstraZeneca PLC lowest share price was 9314.90p and its highest was 12704.00p in the past 12 months.
What is AstraZeneca PLC’s market cap?
Currently, no data Available
When is AstraZeneca PLC’s upcoming earnings report date?
AstraZeneca PLC’s upcoming earnings report date is Jul 25, 2024 which is in 2 days.
How were AstraZeneca PLC’s earnings last quarter?
AstraZeneca PLC released its earnings results on Apr 25, 2024. The company reported 1.595p earnings per share for the quarter, beating the consensus estimate of 1.479p by 0.115p.
Is AstraZeneca PLC overvalued?
According to Wall Street analysts AstraZeneca PLC’s price is currently Undervalued.
Does AstraZeneca PLC pay dividends?
AstraZeneca PLC pays a Annually dividend of 156p which represents an annual dividend yield of 1.88%. See more information on AstraZeneca PLC dividends here
What is AstraZeneca PLC’s EPS estimate?
AstraZeneca PLC’s EPS estimate is £1.53.
How many shares outstanding does AstraZeneca PLC have?
AstraZeneca PLC has 1,550,268,100 shares outstanding.
What happened to AstraZeneca PLC’s price movement after its last earnings report?
AstraZeneca PLC reported an EPS of 1.595p in its last earnings report, beating expectations of 1.479p. Following the earnings report the stock price went up 5.937%.
Which hedge fund is a major shareholder of AstraZeneca PLC?
Currently, no hedge funds are holding shares in GB:AZN
---
AstraZeneca Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
13,206.38p (7.74% Upside)
13,206.38p (7.74% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.83%
12-Months-Change
Fundamentals
Return on Equity
17.17%
Trailing 12-Months
Asset Growth
3.55%
Trailing 12-Months
Company Description
AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
---
AZN Stock 12 Month Forecast
Average Price Target
13,206.38p
▲(7.74% Upside)
Technical Analysis
Best Analysts Covering AZN
1 Year
1 Year Success Rate
21/25 ratings generated profit
1 Year Average Return
+12.44%
reiterated a sell rating 2 months ago
Copying Matthew Weston's trades and holding each position for 1 Year would result in 84.00% of your transactions generating a profit, with an average return of +12.44% per trade.
---